Inphi, Marvell to form $40 billion chip giant
Marvell’s acquisition put’s Inphi’s Thousand Oaks operation in question
Marvell to buy Inphi in $8B semiconductor deal
Marvell Technology Group, a major semiconductor company, announced Oct. 29 it will acquire Inphi, a competitor based in Santa Clara with significant operations in Thousand Oaks, in a cash and stock deal worth about $8 billion. Under the agreement, Marvell will pay Inphi shareholders $66 for each share of Inphi stock, along with 2.323 shares Read More →
Amgen beats expectations in Q3 earnings report
Amgen, one of the biggest biopharmaceutical companies in the world, continued to see growth in the third quarter of 2020, despite the COVID-19 pandemic. The Thousand Oaks-based company saw total revenue of $6.4 billion for the quarter, up 12 percent from the third quarter of 2019. Earnings per share increased 5 percent to $3.43. Both Read More →
Teledyne reports earnings dip
Despite a dip in earnings and sales compared to last year, Teledyne Technologies beat analysts’ expectations with net income of $93.9 million in the third quarter, the company announced Oct. 21. Analysts estimated that Teledyne’s diluted earnings per share would be $2.36 in the third quarter, according to estimates compiled by the Wall Street Journal. Read More →
Arcutis shares up on news of public, private offerings
Arcutis Biotherapeutics saw a 15 percent rise in its share price after it said Sept. 29 that it will offer 4 million shares to the public and sell another $35 million in stock to an affiliate of one of its directors. Arcutis closed at $31.04, a gain of $4.28 after it announced the dual track Read More →
Amgen to join exclusive Dow Jones club
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen teams up with competitors in COVID treatment trial
Amgen has joined two of its competitors in launching a trial for drugs to treat patients with COVID-19. Together with Chicago-based AbbVie and Japanese drugmaker Takeda Pharmaceutical, the Thousand Oaks biotech giant said Aug. 3 it had enrolled the first patients into a clinical trial for the anti-inflammatory drugs Otezla, cenicriviroc and Firazyr. Otezla is Read More →
